| Literature DB >> 35909898 |
Dechuang Zeng1, Xiqiang Tang1, Feng Nong1, Jinyuan Yi1, Yuanxi Yao1, Shiguan Luo1.
Abstract
Objective: To explore the risk factors of recurrence within 1 year after radical resection of non-small cell lung cancer (NSCLC) and construct the nomogram model.Entities:
Year: 2022 PMID: 35909898 PMCID: PMC9325597 DOI: 10.1155/2022/8967162
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.501
Differences in clinical data between groups.
| Clinical data | Recurrence group ( | Non-recurrence group ( | t/ |
|
|---|---|---|---|---|
| Gender, | 0.502 | 0.479 | ||
| Male | 25 (45.45) | 67 (51.15) | ||
| Female | 30 (54.55) | 64 (48.85) | ||
| Age, | 19.256 | <0.001 | ||
| ≥60 years | 28 (50.91) | 25 (19.08) | ||
| <60 years | 27 (49.09) | 106 (80.92) | ||
| BMI, | −0.534 | 0.593 | ||
| <18 kg/m3 | 10 (18.18) | 20 (15.27) | ||
| 18~24 kg/m3 | 29 (52.73) | 69 (52.67) | ||
| >24 kg/m3 | 16 (29.09) | 42 (32.06) | ||
| Family history of NSCLC, | 4.532 | 0.033 | ||
| Yes | 10 (18.18) | 9 (6.87) | ||
| No | 45 (81.82) | 122 (93.13) | ||
| Diabetes mellitus, | 0.061 | 0.806 | ||
| Yes | 7 (12.73) | 15 (11.45) | ||
| No | 48 (87.27) | 116 (88.55) | ||
| Hypertension or coronary heart disease, | 0.889 | 0.346 | ||
| Yes | 12 (21.82) | 21 (16.03) | ||
| No | 43 (78.18) | 110 (83.97) | ||
| Hypoalbuminemia, | 1.296 | 0.255 | ||
| Yes | 10 (18.18) | 34 (25.95) | ||
| No | 45 (81.82) | 97 (74.05) | ||
| Smoking, | 0.089 | 0.766 | ||
| Yes | 21 (38.18) | 47 (35.88) | ||
| No | 34 (61.82) | 84 (64.12) | ||
| Pathological type, | −0.237 | 0.813 | ||
| Adenocarcinoma | 29 (52.73) | 66 (50.38) | ||
| Squamous carcinoma | 20 (36.36) | 51 (38.93) | ||
| Other | 6 (10.91) | 14 (10.69) | ||
| Pathological stage, | 15.745 | <0.001 | ||
| I | 30 (54.55) | 108 (82.44) | ||
| II or III | 25 (45.45) | 23 (17.56) | ||
| N stage, | 1.042 | 0.307 | ||
| N0 | 27 (49.09) | 75 (57.25) | ||
| N1 or N2 | 28 (50.91) | 56 (42.75) | ||
| T stage, | 1.488 | 0.223 | ||
| T1 | 24 (43.64) | 70 (53.44) | ||
| T2 or T3 | 31 (56.36) | 61 (46.56) | ||
| Lesion location, | 1.578 | 0.209 | ||
| Left lung | 32 (58.18) | 63 (48.09) | ||
| Right lung | 23 (41.82) | 68 (51.91) | ||
| Maximum diameter of lesion, | 0.126 | 0.722 | ||
| >3 cm | 38 (69.09) | 87 (66.41) | ||
| ≤3 cm | 17 (30.91) | 44 (33.59) | ||
| Degree of differentiation, | −0.297 | 0.766 | ||
| High | 15 (27.27) | 38 (29.01) | ||
| Medium | 11 (20.00) | 18 (13.74) | ||
| Low | 29 (52.73) | 75 (57.25) | ||
| Number of lymph node metastases, | 14.872 | <0.001 | ||
| >3 | 31 (56.36) | 35 (26.72) | ||
| ≤3 | 24 (43.64) | 96 (73.28) | ||
| Mediastinal lymph node metastasis, | 5.677 | 0.017 | ||
| Yes | 20 (36.36) | 26 (19.85) | ||
| No | 35 (63.64) | 105 (80.15) | ||
| Surgical method, | 0.494 | 0.482 | ||
| Partial lobectomy lung lobe | 42 (76.36) | 106 (80.92) | ||
| Complete lobectomy lung lobe | 13 (23.64) | 25 (19.08) | ||
| Myelosuppression, | 0.249 | 0.618 | ||
| Yes | 24 (43.64) | 52 (39.69) | ||
| No | 31 (56.36) | 79 (60.31) | ||
| Anesthesia method, | 0.589 | 0.443 | ||
| Local anesthesia | 26 (47.27) | 70 (53.44) | ||
| Intravenous anesthesia | 29 (52.73) | 61 (46.56) | ||
| Postoperative complications, | 0.166 | 0.684 | ||
| >3 complications | 40 (72.73) | 99 (75.57) | ||
| ≤3 complications | 15 (27.27) | 32 (24.43) | ||
| Postoperative chronic pain, | 0.150 | 0.699 | ||
| Yes | 29 (52.73) | 65 (49.62) | ||
| No | 26 (47.27) | 66 (50.38) | ||
| Postoperative pulmonary infection, | 0.249 | 0.618 | ||
| Yes | 16 (29.09) | 43 (32.82) | ||
| No | 39 (70.91) | 88 (67.18) | ||
| Surgical history of lung cancer, | 1.010 | 0.315 | ||
| Yes | 5 (9.09) | 19 (14.50) | ||
| No | 50 (90.91) | 112 (85.50) | ||
| Combined COPD, | 32.666 | <0.001 | ||
| Yes | 21 (38.18) | 7 (5.34) | ||
| No | 34 (61.82) | 124 (94.66) | ||
| EGFR mutation status, | −0.334 | 0.738 | ||
| Unknown | 21 (38.18) | 56 (42.75) | ||
| Wild type | 17 (30.91) | 34 (25.95) | ||
| Mutant type | 17 (30.91) | 41 (31.30) | ||
| Preoperative PNI (%) | 51.03 ± 6.64 | 48.56 ± 8.56 | 1.911 | 0.058 |
| Operation time (min) | 133.46 ± 24.16 | 130.67 ± 26.38 | 0.674 | 0.501 |
| Intraoperative blood loss (mL) | 106.25 ± 10.48 | 103.58 ± 12.42 | 1.398 | 0.164 |
| Hemoglobin (g/L) | 73.21 ± 15.36 | 75.22 ± 10.28 | 1.043 | 0.298 |
| Serum albumin (g/L) | 37.08 ± 8.57 | 35.89 ± 10.35 | 0.751 | 0.454 |
| Preoperative plasma D-dimer (mg/L) | 1.74 ± 0.52 | 1.72 ± 0.51 | 0.809 | 0.243 |
| Postoperative plasma D-dimer (mg/L) | 1.23 ± 0.34 | 0.95 ± 0.32 | 5.346 | <0.001 |
| KPS score at first admission (point) | 81.25 ± 10.28 | 83.46 ± 9.27 | 1.436 | 0.153 |
| Ferritin (ng/mL) | 323.25 ± 113.48 | 318.26 ± 92.58 | 0.313 | 0.755 |
| Carcinoembryonic antigen (ng/mL) | 6.72 ± 2.05 | 4.39 ± 1.33 | 9.168 | <0.001 |
| Free prostate specific antigen (ng/mL) | 0.88 ± 0.27 | 0.92 ± 0.11 | 1.439 | 0.152 |
| Carbohydrate antigen 19-9 (U/mL) | 41.22 ± 8.36 | 38.58 ± 12.49 | 1.437 | 0.152 |
| Carbohydrate antigen 724 (U/mL) | 13.58 ± 3.22 | 12.48 ± 4.08 | 1.779 | 0.077 |
Note. BMI = body mass index, NSCLC = non-small cell lung carcinoma, COPD = chronic obstructive pulmonary disease, EGFR = epidermal growth factor receptor, PNI = prognostic nutrition index, and KPS = Karnofsky physical score.
Multivariate logistic regression analysis.
| Independent variable | Assignment |
|
| wals |
|
| 95% CI | |
|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||||
| Age | 0 = <60 years | 0.732 | 0.543 | 1.818 | 0.178 | 2.079 | 0.717 | 6.027 |
| Family history of NSCLC | 0 = No, 1 = yes | −1.012 | 0.805 | 1.580 | 0.209 | 0.363 | 0.075 | 1.762 |
| Pathological stage | 0 = I | 3.048 | 1.101 | 7.669 | 0.006 | 21.077 | 2.437 | 182.287 |
| Number of lymph node metastases | 0 = ≤3, 1 = >3 | 1.719 | 0.577 | 8.875 | 0.003 | 5.580 | 1.801 | 17.291 |
| Mediastinal lymph node metastasis | 0 = No, 1 = yes | −2.105 | 1.099 | 3.669 | 0.055 | 0.122 | 0.014 | 1.050 |
| Combined COPD | 0 = No, 1 = yes | 1.902 | 0.719 | 7.004 | 0.008 | 6.699 | 1.638 | 27.401 |
| Postoperative plasma D-dimer | Measured value | 2.451 | 0.767 | 10.212 | 0.001 | 11.600 | 2.580 | 52.157 |
| Carcinoembryonic antigen | Measured value | 0.879 | 0.175 | 25.196 | <0.001 | 2.409 | 1.709 | 3.397 |
Note. COPD = chronic obstructive pulmonary disease and NSCLC = non-small cell lung carcinoma.
Figure 1Nomogram model of recurrence risk of NSCLC within 1 year after radical resection. Note: COPD = chronic obstructive pulmonary disease and NSCLC = non-small cell lung carcinoma.
Figure 2Internal validation of the nomogram model. (a) ROC curve and (b) calibration curve.
Figure 3External validation of the nomogram model. (a) ROC curve and (b) calibration curve.